Annual report pursuant to Section 13 and 15(d)


12 Months Ended
Sep. 30, 2022
Warrants and Rights Note Disclosure [Abstract]  

Note 13: Warrants

As of September 30, 2020 the Company had 118,029 warrants to purchase shares of Series B Convertible Preferred Stock outstanding with a weighted average exercise price of $20.80 expiring at various timeframes over the next two years. The Company and ICG previously entered into agreements whereby if the warrants were not exercised on or before the applicable expiration date, the applicable expiration date was deemed automatically extended for successive two-year periods, immediately prior to such expiration. During the year ended September 30, 2020, the Company recorded a fair value adjustment of $462 related to the extension of warrants that expired during this period. There were no such adjustments made during the years ended September 30, 2022 and 2021. In January 2021, all warrants were exercised (via cashless exercise) for shares of Series B Convertible Preferred Stock.